CD80抗體—艾普蒂

價(jià)格	詢價(jià)
包裝	20μl	50μl	100μl

最小起訂量	1μl
發(fā)貨地	上海
更新日期	2025-05-15

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:CD80抗體	英文名稱:Mouse Monoclonal CD80 Antibody
品牌: 艾普蒂	產(chǎn)地: 武漢
保存條件: Stored at -20°C for 1217 year. Avoid repeated freeze / thaw cycles.	產(chǎn)品類別: 抗體
重組: 否	應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat	宿主: Mouse
偶聯(lián)物: 無	靶點(diǎn): CD80

驗(yàn)證與應(yīng)用

應(yīng)用及物種

WB	咨詢技術(shù)	Human,Mouse,Rat,Rabbit
IF	咨詢技術(shù)	Human,Mouse,Rat,Rabbit
IHC	1/100 - 1/500	Human,Mouse,Rat,Rabbit
ICC	技術(shù)咨詢	Human,Mouse,Rat,Rabbit
FCM	1/200 - 1/400	Human,Mouse,Rat,Rabbit
Elisa	1/10000	Human,Mouse,Rat,Rabbit

產(chǎn)品詳情

Aliases	B7; BB1; B7-1; B7.1; LAB7; CD28LG; CD28LG1
Entrez GeneID	941
clone	1G3D7
WB Predicted band size	33kDa
Host/Isotype	Mouse IgG1
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human,Mouse,Rat,Rabbit
Immunogen	Purified recombinant fragment of human CD80 (AA: 35-288) expressed in E. Coli.
Formulation	Purified antibody in PBS with 0.05% sodium azide

+ +

Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Flow cytometric analysis of HL-60 cells using CD80 mouse mAb (green) and negative control (red).
Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CD80 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded Mouse spleen using CD80 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded Rat spleen using CD80 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded Rabbit spleen using CD80 mouse mAb with DAB staining.

參考文獻(xiàn)

以下是3篇關(guān)于CD80抗體的假設(shè)性參考文獻(xiàn)示例(基于領(lǐng)域內(nèi)常見研究方向，非真實(shí)文獻(xiàn))：

---

1. **文獻(xiàn)名稱**：CD80/86-CD28/CTLA-4通路在T細(xì)胞活化中的動(dòng)態(tài)調(diào)控

**作者**：Freeman, G.J., et al.

**摘要**：研究揭示了CD80分子與T細(xì)胞表面CD28和CTLA-4受體的差異性結(jié)合機(jī)制，證明抗CD80抗體可阻斷共刺激信號(hào)，抑制T細(xì)胞過度活化，為自身免疫病治療提供理論依據(jù)。

2. **文獻(xiàn)名稱**：抗CD80單抗通過調(diào)節(jié)樹突狀細(xì)胞功能緩解實(shí)驗(yàn)性自身免疫性腦脊髓炎

**作者**：Mirzapianou, S., et al.

**摘要**：在小鼠模型中，抗CD80抗體通過抑制樹突狀細(xì)胞對(duì)髓鞘抗原的呈遞，減少致病性T細(xì)胞增殖，顯著減輕中樞神經(jīng)系統(tǒng)炎癥，提示其在多發(fā)性硬化癥中的潛在應(yīng)用價(jià)值。

3. **文獻(xiàn)名稱**：雙特異性CD80xCD3抗體增強(qiáng)抗腫瘤免疫應(yīng)答的臨床前研究

**作者**：Zhang, Y., et al.

**摘要**：開發(fā)了一種同時(shí)靶向CD80(腫瘤細(xì)胞)和CD3(T細(xì)胞)的雙特異性抗體，在實(shí)體瘤模型中可重定向T細(xì)胞殺傷CD80高表達(dá)腫瘤，并克服PD-1耐藥性，展現(xiàn)協(xié)同治療效果。

---

注：以上為模擬文獻(xiàn)，實(shí)際引用需通過PubMed/Google Scholar等平臺(tái)檢索真實(shí)論文(關(guān)鍵詞：CD80 antibody, B7-1. immune checkpoint)。研究方向可關(guān)注：①免疫共刺激機(jī)制;②腫瘤免疫治療;③自身免疫疾病干預(yù)。

背景信息

CD80. also known as B7-1. is a cell surface protein belonging to the B7 family of immune checkpoint molecules. It is primarily expressed on antigen-presenting cells (APCs), such as dendritic cells and activated B cells. CD80 interacts with two key receptors on T cells: CD28. which provides a co-stimulatory signal for T cell activation, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which delivers an inhibitory signal to dampen immune responses. This dual interaction makes CD80 a critical regulator of T cell activation and tolerance.

CD80-targeting antibodies are designed to modulate immune responses by interfering with these interactions. For example, blocking CD80 binding to CTLA-4 can enhance T cell activity, a strategy explored in cancer immunotherapy. Conversely, inhibiting CD80-CD28 engagement may suppress excessive immune activation in autoimmune diseases. Notably, the CTLA-4-targeting antibody ipilimumab, which indirectly affects CD80/CTLA-4 signaling, was among the first immune checkpoint inhibitors approved for treating metastatic melanoma. However, direct CD80 antibodies remain under investigation, with studies exploring their potential in conditions like lupus, transplant rejection, and hematologic malignancies.

Challenges include balancing therapeutic efficacy with immune-related adverse events and understanding context-dependent roles of CD80 in different diseases. Ongoing research aims to optimize CD80 antibody design, improve selectivity, and identify biomarkers to guide clinical use.

關(guān)鍵字： CD80抗體;CD80;CD80 Antibody;

公司簡(jiǎn)介

是一家科研、開發(fā)、生產(chǎn)和銷售為一體的科技型企業(yè)，

成立日期	2024-07-02 （2年）	注冊(cè)資本	20萬人民幣
員工人數(shù)	1-10人	年?duì)I業(yè)額	￥ 100萬以內(nèi)
主營(yíng)行業(yè)	抗體,蛋白組學(xué),細(xì)胞生物學(xué)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

上海切爾齊生物科技有限公司

VIP 1年

公司成立：2年
注冊(cè)資本：20萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：重組蛋白、抗體、生物試劑
公司地址：青浦區(qū)

進(jìn)入店鋪

詢盤

店內(nèi)推薦

CMTM3抗體—艾普蒂

詢價(jià)

ALK抗體—艾普蒂

詢價(jià)

alphaTubulin（yeast）抗體—艾普蒂

詢價(jià)